Clinical Scorecard: Diagnostic Models for Identifying New Cases of Diabetes Mellitus in Patients with Moderate to Severe COVID-19: The Impact of TyG Index, Body Mass Index, and Inflammatory Biomarkers

At a Glance

Key Highlights

• Insulin resistance is a central driver of newly diagnosed DM in COVID-19 patients.
• The triglyceride-glucose (TyG) index, combined with BMI and inflammatory markers, improves diagnostic accuracy for new DM cases.
• Elevated BMI strongly associates with increased risk of newly diagnosed DM in COVID-19, emphasizing the need for cardiometabolic monitoring.

Guideline-Based Recommendations

Diagnosis

• Use cost-effective surrogate markers such as the TyG index to assess insulin resistance in COVID-19 patients.
• Incorporate BMI and inflammatory cytokine measurements (e.g., IL-6) to enhance prediction of newly diagnosed DM.
• Consider routine metabolic screening in hospitalized COVID-19 patients, especially those with elevated BMI.

Management

• Implement obesity management strategies alongside COVID-19 care to reduce DM risk.
• Monitor and address insulin resistance and inflammation to prevent progression to overt diabetes.
• Integrate cardiometabolic risk assessment into post-COVID-19 follow-up protocols.

Monitoring & Follow-up

• Conduct ongoing cardiometabolic monitoring in COVID-19 survivors with elevated BMI or IR risk factors.
• Track inflammatory biomarkers and glucose metabolism markers during and after COVID-19 infection.
• Validate and refine predictive models for DM risk in diverse populations, particularly in LMICs.

Risks

• Glucocorticoid therapy and systemic inflammation may exacerbate hyperglycemia and insulin resistance.
• High BMI and chronic systemic inflammation increase susceptibility to severe COVID-19 and newly diagnosed DM.
• Lack of validated diagnostic cutoffs for TyG index in LMICs may limit clinical application without further research.

Patient & Prescribing Data

Hospitalized COVID-19 patients with moderate to severe disease, especially those with elevated BMI and risk factors for insulin resistance

Use of TyG index as a practical, cost-effective surrogate for insulin resistance can guide early identification and management of newly diagnosed DM; obesity management and inflammation control are critical adjuncts.

Clinical Best Practices

• Incorporate routine measurement of TyG index, BMI, and inflammatory markers in COVID-19 patient assessments.
• Prioritize cardiometabolic risk evaluation in COVID-19 survivors to identify those at risk for developing DM.
• Apply integrated management approaches addressing obesity, insulin resistance, and inflammation to mitigate DM risk post-COVID-19.
• Adapt predictive models for DM to local populations, validating cutoffs and markers in LMIC settings.
• Recognize the bidirectional relationship between COVID-19 and metabolic dysfunction in clinical decision-making.

References

• Insulin resistance and COVID-19 outcomes
• TyG index as a surrogate marker for insulin resistance
• COVID-19 and newly diagnosed diabetes risk